Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

An Innovation for Treating Orthotopic Pancreatic Cancer by Preoperative Screening and Imaging-Guided Surgery

An Innovation for Treating Orthotopic Pancreatic Cancer by Preoperative Screening and... Purpose: Pancreatic cancer is still associated with a poor outcome and low patient quality of life, which are mainly attributed to the late detection and requirement of distal pancreatectomy with extended resection of pancreatic tumors. Therefore, novel strategies for early screening and precise tumor resection are urgently needed. In this study, we evaluated the feasibility of a low- density lipoprotein receptor (LDLR)-targeted small-molecule contrast agent (peptide-22-Cy7) for early screening with photoacoustic tomography and near-infrared (NIR) imaging as guided surgical navigation to achieve precise resection. Procedure: Normal pancreatic cells (HPDE6-C7) and cancer cells (PANC-1) were respectively used in the in vitro targeting evaluations. The ability of peptide-22-Cy7 for preoperative in vivo pancreatic tumor detection was investigated in a mouse orthotopic pancreatic cancer model (n = 10) using photoacoustic tomography; 18 tumor-bearing mice were further divided into three groups for different treatments. After intravenous injection of peptide-22-Cy7, surgical navigation was conducted through laparotomy. Histopathological analysis was used to further confirm the tumor area and the state of surgical margins. Results: Flow cytometry demonstrated that peptide-22 is highly specific to pancreatic cancer cells, with a fluorescence intensity of approximately 87.3 %. Orthotopic pancreatic tumors with a size of 4 mm could be http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Molecular Imaging and Biology Springer Journals

An Innovation for Treating Orthotopic Pancreatic Cancer by Preoperative Screening and Imaging-Guided Surgery

Download PDF
11 pages

Loading next page...
 
/lp/springer_journal/an-innovation-for-treating-orthotopic-pancreatic-cancer-by-xmfHSpBCzI
Publisher
Springer Journals
Copyright
Copyright © 2018 by World Molecular Imaging Society
Subject
Medicine & Public Health; Imaging / Radiology
ISSN
1536-1632
eISSN
1860-2002
DOI
10.1007/s11307-018-1209-8
Publisher site
See Article on Publisher Site

Abstract

Purpose: Pancreatic cancer is still associated with a poor outcome and low patient quality of life, which are mainly attributed to the late detection and requirement of distal pancreatectomy with extended resection of pancreatic tumors. Therefore, novel strategies for early screening and precise tumor resection are urgently needed. In this study, we evaluated the feasibility of a low- density lipoprotein receptor (LDLR)-targeted small-molecule contrast agent (peptide-22-Cy7) for early screening with photoacoustic tomography and near-infrared (NIR) imaging as guided surgical navigation to achieve precise resection. Procedure: Normal pancreatic cells (HPDE6-C7) and cancer cells (PANC-1) were respectively used in the in vitro targeting evaluations. The ability of peptide-22-Cy7 for preoperative in vivo pancreatic tumor detection was investigated in a mouse orthotopic pancreatic cancer model (n = 10) using photoacoustic tomography; 18 tumor-bearing mice were further divided into three groups for different treatments. After intravenous injection of peptide-22-Cy7, surgical navigation was conducted through laparotomy. Histopathological analysis was used to further confirm the tumor area and the state of surgical margins. Results: Flow cytometry demonstrated that peptide-22 is highly specific to pancreatic cancer cells, with a fluorescence intensity of approximately 87.3 %. Orthotopic pancreatic tumors with a size of 4 mm could be

Journal

Molecular Imaging and Biology – Springer Journals

Published: Jun 1, 2018

References

  • Pancreatic cancer
    Kamisawa, T; Wood, LD; Itoi, T; Takaori, K
  • Current concepts and novel targets in advanced pancreatic cancer
    Michl, P; Gress, TM
  • Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages
    Gillen, S; Schuster, T; Zum Buschenfelde, CM
  • Molecular imaging of pancreatic cancer with antibodies
    England, CG; Hernandez, R; Eddine, SBZ; Cai, W
  • Imaging in pancreatic disease
    Dimastromatteo, J; Brentnall, T; Kelly, KA
  • Current and emerging clinical applications of multispectral optoacoustic tomography (MSOT) in oncology
    McNally, LR; Mezera, M; Morgan, DE
  • General synthesis of high-performing magneto-conjugated polymer core-shell nanoparticles for multifunctional theranostics
    Yan, H; Zhao, LY; Shang, WT; Liu, Z; Xie, W; Qiang, C; Xiong, Z; Zhang, R; Li, B; Sun, X; Kang, F
  • Improvement of surgical results for pancreatic cancer
    Hartwig, W; Werner, J; Jager, D
  • Impact of intraoperative re-resection to achieve R0 status on survival in patients with pancreatic cancer: a single-center experience with 483 patients
    Nitschke, P; Volk, A; Welsch, T; Hackl, J; Reissfelder, C; Rahbari, M; Distler, M; Saeger, HD; Weitz, J; Rahbari, NN
  • Fluorescence-guided surgery with live molecular navigation—a new cutting edge
    Nguyen, QT; Tsien, RY
  • Employing metabolism to improve the diagnosis and treatment of pancreatic cancer
    Halbrook, CJ; Lyssiotis, CA
  • Targeting lipid metabolism of cancer cells: a promising therapeutic strategy for cancer
    Liu, QP; Luo, Q; Halim, A; Song, G
  • Lipid metabolic reprogramming in cancer cells
    Beloribi-Djefaflia, S; Vasseur, S; Guillaumond, F
  • Tumor-induced hyperlipidemia contributes to tumor growth
    Huang, JF; Li, L; Lian, JH; Schauer, S; Vesely, PW; Kratky, D; Hoefler, G; Lehner, R
  • Chemical optimization of new ligands of the low-density lipoprotein receptor as potential vectors for central nervous system targeting
    Malcor, JD; Payrot, N; David, M; Faucon, A; Abouzid, K; Jacquot, G; Floquet, N; Debarbieux, F; Rougon, G; Martinez, J; Khrestchatisky, M; Vlieghe, P; Lisowski, V
  • LDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain glioma
    Zhang, B; Sun, XY; Mei, H; Wang, Y; Liao, Z; Chen, J; Zhang, Q; Hu, Y; Pang, Z; Jiang, X
  • Minimally invasive versus open pancreatoduodenectomy systematic review and meta-analysis of comparative cohort and registry studies
    Rooij, T; Lu, MZ; Steen, W
  • Intraoperative imaging-guided cancer surgery: from current fluorescence molecular imaging methods to future multi-modality imaging technology
    Chi, C; Du, Y; Ye, J
  • Real-time assessment of tissue hypoxia in vivo with combined photoacoustics and high-frequency ultrasound
    Gerling, M; Zhao, Y; Nania, S; Norberg, KJ; Verbeke, CS; Englert, B; Kuiper, RV; Bergström, Å; Hassan, M; Neesse, A; Löhr, JM; Heuchel, RL
  • Advances in real-time multispectral optoacoustic imaging and its applications
    Taruttis, A; Ntziachristos, V
  • Near-infrared squaraine dye encapsulated micelles for in vivo fluorescence and photoacoustic bimodal imaging
    Sreejith, S; Joseph, J; Lin, MJ; Menon, NV; Borah, P; Ng, HJ; Loong, YX; Kang, Y; Yu, SWK; Zhao, Y
  • Photoacoustic tomography: principles and advances
    Xia, J; Yao, JJ; Wang, LV
  • Photoacoustically guided wavefront shaping for enhanced optical focusing in scattering media
    Lai, PX; Wang, LD; Tay, JW; Wang, LV
  • Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma
    Guillaumond, F; Bidaut, G; Ouaissi, M; Servais, S; Gouirand, V; Olivares, O; Lac, S; Borge, L; Roques, J; Gayet, O; Pinault, M; Guimaraes, C; Nigri, J; Loncle, C; Lavaut, MN; Garcia, S; Tailleux, A; Staels, B; Calvo, E; Tomasini, R; Iovanna, JL; Vasseur, S
  • Metabolic scavenging by cancer cells: when the going gets tough, the tough keep eating
    Michalopoulou, E; Bulusu, V; Kamphorst, JJ
  • Selecting tumor-specific molecular targets in pancreatic adenocarcinoma: paving the way for image-guided pancreatic surgery
    Geus, SWL; Boogerd, LSF; Swijnenburg, RJ; Mieog, JSD; Tummers, WSFJ; Prevoo, HAJM; Sier, CFM; Morreau, H; Bonsing, BA; van de Velde, CJH; Vahrmeijer, AL; Kuppen, PJK
  • Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer
    Adiseshaiah, PP; Crist, RM; Hook, SS; McNeil, SE
  • Emerging inorganic nanomaterials for pancreatic cancer diagnosis and treatment
    Yang, F; Jin, C; Subedi, S; Lee, CL; Wang, Q; Jiang, Y; Li, J; di, Y; Fu, D
  • Tumor-specific uptake of fluorescent bevacizumab-IRDye800CW microdosing in patients with primary breast cancer: a phase I feasibility study
    Lamberts, LE; Koch, M; Jong, JS; Adams, ALL; Glatz, J; Kranendonk, MEG; Terwisscha van Scheltinga, AGT; Jansen, L; Vries, J; Lub-de Hooge, MN; Schröder, CP; Jorritsma-Smit, A; Linssen, MD; Boer, E; Vegt, B; Nagengast, WB; Elias, SG; Oliveira, S; Witkamp, AJ; Mali, WPTM; Wall, E; Diest, PJ; Vries, EGE; Ntziachristos, V; Dam, GM
  • Dye-conjugated single-walled carbon nanotubes induce photothermal therapy under the guidance of near-infrared imaging
    Liang, XY; Shang, WT; Chi, CW; Zeng, C; Wang, K; Fang, C; Chen, Q; Liu, H; Fan, Y; Tian, J